title: Different strategies of mixed chimerism induction may determine stem/progenitor cell populations in recipient mice.
abstract: Mixed chimerism has been suggested to induce tolerance to transplanted alloantigens. As the precise influence of mixed chimerism induction on the host organism has still not been fully elucidated, the aim of the present study was to explore this phenomenon in relation to the stem cell compartment. The experiment was performed on B6.SJL-Ptprc(a)Pep3(b) mice. Mixed chimerism induction protocols involved 3 Gy TBI (Day -1 of the experiment), injection of 20-30 × 10(6) Balb C bone marrow cells (Day 0), and administration of blocking antibodies against CD40L (Day 0 and Day 4), anti-CD8 (Day -2) with/without anti-NK1.1 (Day -3). Selected groups of mice were also treated with cyclophosphamid (175 mg/kg) on Day 2. The presence of mixed chimerism was assessed in peripheral blood, bone marrow, and spleen, as well as in various subpopulations of leukocytes (CD4(+), CD8(+), CD45/B220(+), Gr-1(+), lin(-)/Sca-1(+)/c-kit(-), lin(-)/Sca-1(+)/c-kit(+), lin(-)/Sca-1(-)/c-kit(+)). Furthermore, the percentage of stem/progenitor cells (lin(-)/Sca-1(+)/c-kit(-), lin(-)/Sca-1(+)/c-kit(+), lin(-)/Sca-1(-)/c-kit(+), VSEL, HSC) was analysed for the first time in bone marrow and peripheral blood of chimeric mice. The range of mixed chimerism differed significantly among various cell populations: it was lowest in CD8-positive cells and lin(-)/Sca-1(+)/c-kit(-) cells, and highest in granulocytes. The induction of mixed chimerism revealed a significant impact on the stem/progenitor cell frequency in recipient mice, providing potential therapeutic insights into the long-term immunologic tolerance observed in chimeric mice. Collectively, these findings contribute to further optimization of mixed chimerism induction protocols and might help in the introduction of this phenomenon into clinical practice.
authors.affiliation: Department of General Pathology, Pomeranian Medical University, Szczecin, Poland. poziomka@med.pam.szczecin.pl
authors.forename: Magdalena
authors.initials: M
authors.lastname: Baśkiewicz-Hałasa
authors.forename: Ewa
authors.initials: E
authors.lastname: Pius
authors.forename: Maciej
authors.initials: M
authors.lastname: Hałasa
authors.forename: Violetta
authors.initials: V
authors.lastname: Dziedziejko
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Grymuła
authors.forename: Bogusław
authors.initials: B
authors.lastname: Machaliński
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology; D015703:Antigens, CD / Q000032:analysis*; D001854:Bone Marrow Cells / Q000276:immunology / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004307:Dose-Response Relationship, Radiation; D005434:Flow Cytometry / Q000379:methods; D007108:Immune Tolerance; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011829:Radiation Dosage; D018183:Transplantation Chimera / Q000276:immunology*; D019172:Transplantation Conditioning / Q000379:methods; D014916:Whole-Body Irradiation
chemical_list: D019138:Antibodies, Blocking; D015703:Antigens, CD; D003520:Cyclophosphamide; D019009:Proto-Oncogene Proteins c-kit; D017493:Leukocyte Common Antigens; C516770:Ptprc protein, mouse